机构：[1]Chinese Acad Med Sci, Urol, Canc Hosp, Beijing, Peoples R China[2]First Hosp Ningbo, Urol, Ningbo, Peoples R China[3]Harbin Med Univ, Urol, Affiliated Hosp 4, Harbin, Peoples R China[4]Qilu Hosp Shandong Univ, Urol, Jinan, Peoples R China[5]Capital Med Univ, Urol, Beijing Tongren Hosp, Beijing, Peoples R China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[6]Peking Union Med Coll Hosp, Urol, Beijing, Peoples R China[7]Chinese Acad Med Sci, Pathol, Canc Hosp, Beijing, Peoples R China[8]Chinese Acad Med Sci, Med Oncol, Canc Hosp, Beijing, Peoples R China
第一作者机构：[1]Chinese Acad Med Sci, Urol, Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Xing N.,Han S.,Jiang J.,et al.Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer[J].ANNALS OF ONCOLOGY.2021,32:S714-S714.doi:10.1016/j.annonc.2021.08.099.
APA：
Xing, N.,Han, S.,Jiang, J.,Xu, W.,Shi, B....&Zhang, W..(2021).Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.ANNALS OF ONCOLOGY,32,
MLA：
Xing, N.,et al."Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer".ANNALS OF ONCOLOGY 32.(2021):S714-S714
医学